Attached files
file | filename |
---|---|
8-K - FORM 8-K - BIOCLINICA INC | w80105e8vk.htm |
Exhibit 99.1
Company Contact Jim Dorsey |
BioClinica, Inc. |
267-757-3040 |
Investor Contact Linda Decker |
Financial Media Bill Gordon |
Porter, LeVay & Rose, Inc. |
212-564-4700 |
Trade Media Beth Nestlerode |
Diccicco Battista Communications |
484-342-3600 |
FOR IMMEDIATE RELEASE
BIOCLINICA APPOINTS JAMES W. LOVETT TO ITS BOARD OF DIRECTORS
- Executive With Industry, Legal and Regulatory Experience -
NEWTOWN, PA, October 12, 2010 BioClinica, Inc., (NASDAQ: BIOC), a leading provider of clinical
trial management services, today announced that it has appointed James W. Lovett to its Board of
Directors, increasing the size of the Board to nine members.
Mr. Lovett, age 45, currently serves as General Counsel of Covance Inc., a NYSE-listed drug
development company with more than 10,000 employees (Covance), and is responsible for global
legal affairs, corporate governance, government relations, and corporate security for Covance.
Mr. Lovett also serves as Secretary to the Covance Board of Directors and is a member of the
Global Leadership Council, Covances executive committee. He also chairs the Covance Regulatory
Leadership Team and co-chairs the Covance Enterprise Risk Council. Mr. Lovett joined Covance as
General Counsel in 2001. In addition to his corporate staff responsibilities, Mr. Lovett has led
Covances Nutritional Chemistry & Food Safety Services since 2008. During 2004-2005, Mr. Lovett
also served as acting General Manager of Covance Interactive Voice Response Services.
Prior to joining Covance, Mr. Lovett was Associate General Counsel and Assistant Secretary of
FMC Corporation, a Fortune 500 manufacturing conglomerate (FMC). Before joining FMC, Mr. Lovett
was a partner at McDermott, Will & Emery, in Chicago, Illinois, and an associate with Wilmer,
Cutler & Pickering in Washington, DC. Mr. Lovett is a member (previously Chair) of the Legal and
Government Affairs Committee of the Association of Clinical Research Organizations. Mr. Lovett is
also on the Board of Directors of Scholar Academies, a nonprofit network of charter schools in
Philadelphia and Washington, DC.
Mr. Lovetts education includes a J.D. from Harvard Law School, cum laude, and a B.A. in history
from Northwestern University.
-more-
With his depth of experience in the drug development industry, and his expertise in legal and
regulatory affairs, we are confident that James Lovett will make significant contributions to our
Board of Directors on behalf of all of our shareholders. As we continue to increase our footprint
in the clinical trial management services industry, Jamess insight and guidance will be crucial
to our efforts, said David E. Nowicki, Chairman of BioClinica.
Follow BioClinica on the Trial Blazers blog at http://info.bioclinica.com/blog, and on twitter at
http://twitter.com/bioclinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical
trial management services. BioClinica supports pharmaceutical and medical device innovation with
imaging core lab, internet image transport, electronic data capture, interactive voice and web
response, Microsoft Office-Smart clinical trial management and clinical supply chain design and
optimization solutions. BioClinica services maximize efficiency and manageability throughout all
phases of the clinical trial process. With more than 20 years of experience and over 2,000
successful trials to date, BioClinica has supported the clinical development of many new medicines
from early phase trials through final approval. BioClinica operates state-of-the-art,
regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical
and data management services from offices in the United States, Europe and Asia. For more
information, please visit www.bioclinica.com.
Certain matters discussed in this press release are forward-looking statements intended to
qualify for the safe harbors from liability established by the Private Securities Litigation
Reform Act of 1995. In particular, the Companys statements regarding trends in the marketplace
and potential future results are examples of such forward-looking statements. The forward-looking
statements include risks and uncertainties, including, but not limited to, the consummation and
the successful integration of current and proposed acquisitions, the timing of projects due to the
variability in size, scope and duration of projects, estimates and guidance made by management
with respect to the Companys financial results, backlog, critical accounting policies, regulatory
delays, clinical study results which lead to reductions or cancellations of projects, and other
factors, including general economic conditions and regulatory developments, not within the
Companys control. The factors discussed herein and expressed from time to time in the Companys
filings with the Securities and Exchange Commission could cause actual results and developments to
be materially different from those expressed in or implied by such statements. The
forward-looking statements are made only as of the date of this press release and the Company
undertakes no obligation to publicly update such forward-looking statements to reflect subsequent
events or circumstance. You should review the Companys filings, especially risk factors contained
in the Form 10-K and the recent Form 10-Q.
######